Solara Active Pharma Sciences Ltd provides further updates on Ranitidine Hydrochloride APISolara Active Pharma Sciences Ltd (Solara) (NSE: SOLARA; BSE: 541540) today shared further updates on Ranitidine Hydrochloride API. The Company, in September 2019, received request for information from USFDA, EDQM & TGA to provide test data on N-nitrosodimethylamine (NDMA) content in Ranitidine Hydrochloride API and voluntarily suspended production and distribution of Ranitidine for all the markets.
The Company would like to share that TGA1, on October 22, 2019, published results of 135 samples of Ranitidine medications from 10 Australian companies available in the market. As per the results, out of the 135 batches, only 24 oral solid dosage batches were found to have levels of NDMA within the acceptable limit of 0.3 ppm and all these batches were produced using the API supplied by Solara.
These tests were conducted adopting the recently recommended test methods by USFDA.
Shares of Solara Active Pharma Sciences Ltd was last trading in BSE at Rs.398.2 as compared to the previous close of Rs. 418.05. The total number of shares traded during the day was 5278 in over 936 trades.
The stock hit an intraday high of Rs. 421.9 and intraday low of 390.9. The net turnover during the day was Rs. 2132463.